May. 20, 2024
SEATTLE & INNSBRUCK, AUSTRIA — Sound Pharmaceuticals (SPI) has announced that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI). The goal of this Phase 2 SPI-1005 (ebselen) trial is to reduce the loss of residual hearing during and after CI. Ebselen is a novel anti-inflammatory compound that